Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpegaldesleukin in Psoriasis
NCT04119557Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rezpegaldesleukin in psoriasis (3 arms), sponsored by Nektar Therapeutics. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Nov 2019; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04119557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119557.